138 related articles for article (PubMed ID: 7684443)
1. Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo.
Matsubara S; Matsubara R; Kusumi I; Koyama T; Yamashita I
J Pharmacol Exp Ther; 1993 May; 265(2):498-508. PubMed ID: 7684443
[TBL] [Abstract][Full Text] [Related]
2. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Matsubara R
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
[TBL] [Abstract][Full Text] [Related]
3. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics.
Meller E; Bohmaker K; Goldstein M; Friedhoff AJ
J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276
[TBL] [Abstract][Full Text] [Related]
5. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
Stockmeier CA; DiCarlo JJ; Zhang Y; Thompson P; Meltzer HY
J Pharmacol Exp Ther; 1993 Sep; 266(3):1374-84. PubMed ID: 8103793
[TBL] [Abstract][Full Text] [Related]
6. In vivo occupation of dopamine D1, D2 and serotonin (5-HT)2A receptors by sertindole in the rat brain.
Takahashi Y; Kusumi I; Ishikane T; Matsubara S; Koyama T
J Psychiatry Neurosci; 1998 May; 23(3):157-62. PubMed ID: 9595889
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
8. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
Meltzer HY; Matsubara S; Lee JC
J Pharmacol Exp Ther; 1989 Oct; 251(1):238-46. PubMed ID: 2571717
[TBL] [Abstract][Full Text] [Related]
9. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.
Meltzer HY; Matsubara S; Lee JC
Psychopharmacol Bull; 1989; 25(3):390-2. PubMed ID: 2576319
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs.
Lidow MS; Goldman-Rakic PS
J Pharmacol Exp Ther; 1997 Nov; 283(2):939-46. PubMed ID: 9353417
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
13. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
Szczepanik AM; Brougham LR; Roehr JE; Conway PG; Ellis DB; Wilmot CA
J Pharmacol Exp Ther; 1996 Aug; 278(2):913-20. PubMed ID: 8768747
[TBL] [Abstract][Full Text] [Related]
15. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
16. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
Burger LY; Martin-Iverson MT
Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
[TBL] [Abstract][Full Text] [Related]
17. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
[TBL] [Abstract][Full Text] [Related]
18. Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies.
Haraguchi K; Ito K; Kotaki H; Sawada Y; Iga T
Drug Metab Dispos; 1997 Jun; 25(6):675-84. PubMed ID: 9193868
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors.
Czyrak A; Jaros T; Moryl E; Maj J
Pharmacopsychiatry; 1993 Mar; 26(2):53-8. PubMed ID: 7690975
[TBL] [Abstract][Full Text] [Related]
20. In vivo occupation of dopamine D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain.
Takahashi Y; Kusumi I; Ishikane T; Koyama T
J Neural Transm (Vienna); 1998; 105(2-3):181-91. PubMed ID: 9660096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
